

Figure S1. Sorafenib plasma concentration versus time at steady state in patients with hepatocellular carcinoma (studies 10874 HCC, 11849 HCC, 14898 HCC, and 100554 HCC), renal cell carcinoma (studies 11213 RCC, 11515 RCC, and 11559 RCC), and differentiated thyroid carcinoma (study 14295 DTC; DECISION). Concentration data from the same patient are connected by a dashed line. The solid lines represented a Loess fit to indicate a potential trend.

